← boardnext 2026-12-01next 2028-05-31
ZNTL
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Incdistress 5/10 · elevated risk$4.69+4%today-29% from 52w high
Lead: Cyclin E1-positive platinum-resistant ovarian cancer · est. market ~$8B (approx, global)
Revenue
pre-revenue
Liquidity
$32M
Runway
0.3 yrs
Shares 1y
-1%
Price & events
+44.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
+4.1%
1D
+2.5%
1W
+27.4%
1M
+20.5%
3M
+59.4%
6M
+210.4%
1Y
+11.3%
2Y
-90.8%
5Y
-91.1%
All
Overview
- Market Cap
- $333.61M
- Volume
- 160.60K
- 52 Week Range
- $1.28 – $6.61
- Total Shares
- 71.19M
- Float Shares
- 48.56M
- Short %
- 10.32%
- % Held by Insiders
- 22.84%
- % Held by Institutions
- 61.87%
- RVOL
- 0.12x
- Beta
- 1.93
Pipeline stages · 2 programs
Azenosertib, Carboplatin, Pegylated liposomal doxorubicin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Investigator's choice of Chemotherapy, Azenosertib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12-01 Estimated 50% readout ~2027-01-15 | Phase 2 | azenosertib | High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | — | recruiting |
| 2028-05-31 Estimated 50% readout ~2028-08-14 | Phase 3 | Investigator's choice of Chemotherapy, Azenosertib | Ovarian Cancer | — | recruiting |
| 2028-06-30 Estimated 50% readout ~2028-07-30 | Phase 1 | Azenosertib, Carboplatin, Pegylated liposomal doxorubicin | Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer | — | recruiting |
Catalyst news & presentations · 16
- year end 2026Guided 40%readoutPhase 2azenosertib · DENALI Part 2 topline readoutSEC 8-K
- year end 2026readoutazenosenosertib · Topline data from DENALI Part 2SEC 8-K
- year-end 2026Guided 40%enrollment completesecondaryPhase 2azenosertib · Complete enrollment in all cohorts of DENALI Part 2SEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- Q2 2026trial initiationsecondaryPhase 2azenosertib · Initiation of DENALI Part 2c cohort enrollmentSEC 8-K
- first half of 2026readoutPhase 2azenosertib · DENALI Part 2a dose confirmationSEC 8-K
- May 29 – June 2, 2026conferencedata presentationsecondaryPhase 1azenoseritib · Part 1 data from MUIR trial at ASCO 2026SEC 8-K
- first half of 2025trial initiationsecondaryazenosenosertib · Initiate enrollment of DENALI Part 2SEC 8-K
- June 4, 2025, at 9:55 a.m. ETconferencedata presentationsecondaryJefferies Healthcare Conference presentationSEC 8-K
- May 31, 2025conferencedata presentationsecondaryPhase 1azenozertib · Phase 1 dose escalation results of azenosertib in combination with encorafenib and cetuximab.SEC 8-K
- May 27, 2025, at 11:00 a.m. ETconferencedata presentationsecondaryTD Cowen's 6th Annual Oncology Innovation Summit presentationSEC 8-K
- May 20, 2025, at 11:30 a.m. ETconferencedata presentationsecondaryH.C. Wainwright 3rd Annual BioConnect Investor Conference presentationSEC 8-K
- April 25-30, 2025conferencedata presentationsecondaryazenosertib · Presented four posters at AACR 2025 Annual MeetingSEC 8-K
- 2025-01-29trial discontinuedazenosenosertib · Discontinued azenosertib+niraparib combination due to lack of efficacious exposuresSEC 8-K
- 2025-01-29fda agreementazenosenosertib · FDA aligned on DENALI Part 2 design allowing seamless enrollment across Parts 2a and 2bSEC 8-K
- 2024-09-16fda agreementazenosertib · FDA lifted partial clinical hold and cleared resumption of enrollment in all ongoing azenosertib clinical studies with no changes in the clinical development plan.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $7 (+42% upside) · 9 analysts
- 2026-07-17MizuhoOutperform
- 2026-04-10GuggenheimBuy
- 2026-03-27GuggenheimBuy
- 2025-11-12Morgan StanleyEqual-Weight
- 2025-08-07Wells FargoEqual-Weight
- 2025-05-15HC Wainwright & Co.Buy
Competitors — Cyclin E1-positive platinum-resistant ovarian cancer
- none identified
Recent news
- 2026-07-21ManpowerGroup posts upbeat Q2 earnings, joins Docebo, Zentalis Pharmaceuticals and other big stocks moving higher on Friday - MSN
- 2026-07-20ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally? - Yahoo! Finance Canada
- 2026-07-20ZENTALIS PHARMACEUTICALS INC : MIZUHO INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $8 - Bitget
- 2026-07-19ZNTL Jumps As Mizuho Targets Upside On Cancer Drug - StocksToTrade
- 2026-07-17Zentalis' Azenosertib Accepted for Rapid ESMO Survival Presentation - Stock Titan
- 2026-07-17ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Movin - Benzinga
- 2026-07-17Mizuho initiates Zentalis Pharmaceuticals stock at Outperform By Investing.com - Investing.com South Africa
- 2026-07-17Mizuho initiates Zentalis Pharmaceuticals stock at Outperform - Investing.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.